Body Vision Medical

The company's core product is the LungVision™ platform, an FDA-cleared and CE-marked system that addresses challenges in early lung cancer detection. The platform uses artificial intelligence to transform standard 2D X-ray images from any conventional C-arm into real-time 3D tomographic images. This technology, known as AI Tomo®, allows pulmonologists and thoracic surgeons to see the precise location of a lesion during a bronchoscopy, navigate to it, and visually confirm that a biopsy tool is correctly placed. This process overcomes the common issue of CT-to-body divergence, where a lesion's position shifts between a pre-operative CT scan and the actual procedure, thereby improving the diagnostic accuracy and yield from biopsies of small, hard-to-access nodules.

Body Vision Medical operates on a business model centered on selling its LungVision™ system to hospitals and cancer centers. The platform is designed to be cost-effective by integrating with existing bronchoscopy equipment, including robotic platforms, avoiding the need for expensive new hardware. The company generates revenue through the sale of the platform and its associated disposable catheters. Headquartered in Ramat Hasharon, Israel, with a U.S. base in Waltham, MA, the company serves a global market, including top institutions in the U.S., Europe, and Asia. The firm has raised a total of $28.5M in funding over two rounds, including a $20M Series C round in 2019.